




Advancing Therapeutics.
Improving Lives.



September 3, 2015

Dr Jinliang Li
Shanghai Desano Pharmaceuticals Ltd
Building No 5, 1999 Zhangheng Road
Shanghai 201203
China

RE: TAF Combination Products

To Whom it May Concern:

Reference is made to that certain Amended and Restated License Agreement between Shanghai Desano Pharmaceuticals Investment Co. Ltd. (“you”), the Medicines Patent Pool Foundation and Gilead Sciences, Inc. (“Gilead”), dated as of August 1, 2015, and to any subsequent modification thereof (the “License Agreement”). All capitalized terms used in this letter but not defined herein shall have the meanings assigned to such terms in the License Agreement.

This letter is to clarify that Section 2.5(b)(ii) of the License Agreement is not intended to prohibit you from manufacturing or selling any TAF Combination Products following Gilead’s receipt of Marketing Approval for the TAF Quad. Accordingly, following Gilead’s receipt of Marketing Approval by the FDA for the TAF Quad, Gilead hereby agrees that your manufacture or sale of any TAF Combination Product (including without limitation the TAF Quad) in accordance with the terms of the License Agreement will not constitute a breach of Section 2.5(b)(ii) of the License Agreement.

If you have any further questions, please contact Aastha Gupta at agupta@medicinespatentpool.org.

Kind Regards,

Clifford Samuel
Senior Vice President
Access Operations & Emerging Markets
Gilead Sciences, Inc.

Greg Perry
Executive Director
Medicines Patent Pool Foundation